O'Neill Institute | July 12, 2021Read the Publication
Innovative payment models are novel drug procurement plans being used by a growing number of states to secure hepatitis C treatment medication for persons receiving state-sponsored health care. This paper analyzes similarities and contrasts in enacted and emerging innovative payment models in three states—Louisiana, Washington, and Michigan. It describes varied applications of these types of models, progress to-date at increasing HCV treatment rates, and assesses how the plans currently being implemented are impacting access to treatment. Finally, the paper provides recommendations on how existing and future models can be adapted to optimize outcomes that will lead to HCV elimination.